NRT & Bupropion Mechanisms of Efficacy in Smokers

描述（由申请方提供）：本修订提案的第一个目的是准确评估3个不同治疗组戒烟66天后戒烟症状的持续时间和轨迹以及相关生物行为指数：1）安非他酮SR（BIJP），2）尼古丁透皮贴剂（TNP）和3）安慰剂。通过使用旨在最大限度地减少禁欲和最大限度地减少研究脱落的程序，将最大限度地提高研究灵敏度和准确度。第二个目的是描述BUP和TNP促进禁欲的大脑和心理机制。虽然BUP和TNP在促进戒烟方面的功效已被反复证明，但对介导这种功效的机制知之甚少。这个竞争性的延续建议的最终主要目标是表征心理和大脑机制介导的BUP和TNP对戒烟和戒断症状的有益影响的个体差异。第二个目标是评估一组创新的大脑和生物行为的注意力和影响措施预测复发的能力。 为了实现这些目标，将在66天的戒烟期间集中评估在有或没有TNP和BUP的帮助下戒烟的效果，依赖性测量将是情绪、警惕性、对吸烟和情绪刺激的注意力偏差以及相关的生理测量（情绪状态和特征的静息EEC激活和激活不对称指数，以及由情绪和吸烟刺激引起的事件相关潜在活动）。吸烟者将被随机分配到三个立即戒烟组中的一个（每组N = 80）：（1）安非他酮+安慰剂贴剂（2）安慰剂药丸→尼古丁贴剂，和（3）安慰剂药丸+安慰剂贴剂或第四组（对照组）（N = 60），将在最后一次实验后戒烟（在其他受试者完成66天戒烟期后）。3个治疗组和对照组中的受试者将在实验期间的相同时间点接受相同的生物行为测量评估。据推测，BUF和TNP将有共同的和独特的机制，他们减少戒断症状，性别和人格特质将缓和这些治疗的效果。(Note* 为了避免最后一次的情绪和唤醒效应，受试者实际上将戒烟67天，但生物行为测量将在戒烟66天时收集。

DESCRIPTION (provided by applicant): The first aim of this revised proposal is to accurately assess the duration and trajectories of smoking abstinence symptoms and associated biobehavioral indices across 66 days of quitting smoking in 3 different treatment groups: 1) bupropion SR (BIJP), 2) transdermal nicotine patch (TNP), and 3) a placebo. Study sensitivity and accuracy will be maximized by using procedures designed to maximize abstinence and minimize study dropout. The second aim is to characterize brain and psychological mechanisms by which BUP and TNP promote abstinence. While the efficacies of BUP and TNP in promoting smoking abstinence have been repeatedly demonstrated little is known about the mechanisms mediating this efficacy. The final primary goal of this competitive continuation proposal is to characterize individual differences in psychological and brain mechanisms mediating the beneficial effects of BUP and TNP on smoking abstinence and withdrawal symptoms. A secondary goal is to assess the ability of a battery of innovative brain and biobehavioral measures of attention and affect to predict relapse. To achieve these goals the effects of quitting smoking with or without the help of TNP and BUP will be assessed intensively across 66 days of abstinence, Dependent measures will be mood, vigilance, attentional bias to smoking and emotional stimuli, and related physiological measures (resting EEC activation and activation asymmetry indices of affective states and traits, and event-related potential activity elicited by emotional and smoking stimuli). Smokers will be randomly assigned to one of three immediate-quit groups (N = 80 per group): (1) bupropion + placebo patch (2) placebo pill ¿ nicotine patch, and (3) placebo pill + placebo patch or to a fourth (control) group (N = 60) that will quit after the final experimental session (after the other subjects have completed their 66-day abstinence period). Subjects in the 3 treatment groups and the control group will have the same set of biobehavioral measures assessed during the experimental sessions at the same points in time. It is hypothesized that BUF and TNP will have both common and unique mechanisms by which they reduce withdrawal symptoms and that gender and personality traits will moderate the effects of these treatments. (Note,* To avoid final-session mood and arousal effects subjects will actually quit for 67 days, but biobehavioral measures will be collected on the 66 day of abstinence